Rani announces positive Phase 1 topline results for oral ustekinumab biosimilar RT-111

Rani Therapeutics Holdings, Inc.

RT-111 achieved 84% bioavailability vs subcutaneous Stelara injection; higher Cmax and shorter Tmax observed.
No serious adverse events; mild transient AEs resolved without intervention; no participants withdrew.
Celltrion holds right of first negotiation to acquire worldwide rights to RT-111 after successful Phase 1.
This marks Rani's third successful Phase 1 trial using RaniPill technology; potential differentiated oral dosing for psoriasis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.